TP53 and myelodysplastic syndrome: Patients with MDS accompanied by TP53 abnormalities had poor long-term survival when treated with HMA-based therapies, with a median OS of 7.3 months, 1-year OS rate of 42.2%, and 2-year OS rate of 21.5% (Figure 1).